Dosage and Administration:
The recommended dose of Etodolac Tablets is 4.5 to 6.8
mg/lb body weight (10 to 15 mg/kg) administered once daily. Due to
capsule sizes and scoring, dogs weighing less than 11 lb (5 kg) cannot
be accurately dosed. The effective dose and duration should be based on
clinical judgment of disease condition and patient tolerance of drug
treatment. The initial dose level should be adjusted until a
satisfactory clinical response is obtained, but should not exceed 15
mg/kg once daily.Warnings:
Do not use in cats. For use in dogs only.
The safe use of Etodolac Tablets in dogs less than 12
months of age, pregnant, breeding or lactating dogs has not been
established. Owners should be advised to observe for
signs of potential drug reactions. If additional pain medication is
warranted after administration of the daily dose of Etodolac,
alternative analgesia should be considered. The use of another NSAID is
As a class, cyclooxygenase inhibitory NSAIDs may be
associated with gastrointestinal, renal, and hepatic toxicity.
Sensitivity to drug-associated adverse effects varies with the
individual patient. Dogs that have experienced adverse reactions from
one NSAID may experience adverse reactions from other NSAIDs. Dogs at
greatest risk for adverse events are those that are dehydrated, on
concomitant diuretic therapy, or those with renal, cardiovascular,
and/or hepatic dysfunction. Concurrent administration of potentially
nephrotoxic drugs should be carefully approached and monitored. NSAIDs
may inhibit the prostaglandins that maintain normal homeostatic
function. Such anti-prostaglandin effects may result in clinically
significant disease in patients with underlying or pre-existing disease
that has not been previously diagnosed. Since NSAIDs possess the
potential to induce gastrointestinal ulceration and/or gastrointestinal
perforation, concomitant use of Etodolac with other anti-inflammatory
drugs, such as other NSAIDs or corticosteroids, should be avoided.
The use of concomitantly protein-bound drugs with
Etodolac has not been studied in dogs. Commonly used protein-bound drugs
include cardiac, anticonvulsant and behavioral medications. The
influence of concomitant drugs that may inhibit metabolism of Etodolac
has not been evaluated. Drug compatibility should be monitored in
patients requiring adjunctive therapy. Consider appropriate washout
times when switching from one NSAID to another or when switching from
corticosteroid use to NSAID use.
Treatment with Etodolac Tablets should be terminated if
signs such as inappetence, emesis, fecal abnormalities, or anemia are
observed. Dogs treated with non-steroidal anti-inflammatory drugs on a
continuing basis, including etodolac, should be evaluated periodically
to ensure that the drug is still necessary and well tolerated.
Etodolac Tablets, as with other non-steroidal
anti-inflammatory drugs, may exacerbate clinical signs in dogs with
pre-existing or occult gastrointestinal, hepatic or cardiovascular
abnormalities, blood dyscrasias, or bleeding disorders.Adverse Reactions:
As with other drugs in the NSAID class, adverse
responses to Etodolac Tablets may occur.
Store at controlled room temperature, 15-30°C (59-86°F).
diarrhea, inappetence, gastroenteritis, gastrointestinal bleeding,
melena, gastrointestinal ulceration, hypoproteinemia, elevated
Hepatic: Abnormal liver
function test(s), elevated hepatic enzymes, icterus, acute hepatitis.
hemolytic anemia, thrombocytopenia, prolonged bleeding time.
Senses: Ataxia, paresis, aggression, sedation, hyperactivity,
disorientation, hyperesthesia, seizures, vestibular signs,
Renal: Polydipsia, polyuria,
urinary incontinence, azotemia, acute renal failure, proteinuria,
Pruritus, dermatitis, edema, alopecia, urticaria.
Etodolac Tablets are supplied in bottles
containing 100 tablets.
Federal (U.S.A.) law restricts
this drug to use by or on the order of a licensed veterinarian